NASDAQ:NXTM - NxStage Medical Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$28.00 +0.12 (+0.43 %)
(As of 07/16/2018 06:00 AM ET)
Previous Close$28.00
Today's Range$27.87 - $28.11
52-Week Range$22.70 - $29.93
Volume174,766 shs
Average Volume342,262 shs
Market Capitalization$1.86 billion
P/E Ratio-127.27
Dividend YieldN/A
Beta-0.07
NxStage Medical logoNxStage Medical, Inc., a medical technology company, develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure. Its primary product includes the System One, a portable hemodialysis system, which is used primarily for home hemodialysis and a range of dialysis therapies to deliver in the home setting. The company operates through three segments: System One, In-Center, and Services. The System One segment sells and rents the NxStage System One and PureFlow SL dialysate preparation equipment, as well as sells disposable products in the home and critical care market for the treatment of end-stage renal disease (ESRD) patients in the home or a home-like setting and in the critical care market for the treatment of hospital-based patients with acute kidney failure or fluid overload. The In-Center segment sells blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers, and needles for apheresis. The Services segment offers dialysis services to patients at NxStage Kidney Care dialysis centers. As of February 3, 2018, it had 21 centers. NxStage Medical, Inc. markets its products through direct sales to dialysis clinics and hospitals in the United States, the United Kingdom, and Canada, as well as through distributors in Europe and internationally. The company was formerly known as QB Medical, Inc. and changed its name to NxStage Medical, Inc. NxStage Medical, Inc. was founded in 1998 and is headquartered in Lawrence, Massachusetts.

Receive NXTM News and Ratings via Email

Sign-up to receive the latest news and ratings for NXTM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Electromedical equipment
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:NXTM
CUSIP67072V10
Phone978-687-4700

Debt

Debt-to-Equity RatioN/A
Current Ratio3.51
Quick Ratio2.39

Price-To-Earnings

Trailing P/E Ratio-127.27
Forward P/E Ratio-2,800.00
P/E GrowthN/A

Sales & Book Value

Annual Sales$393.94 million
Price / Sales4.73
Cash Flow$0.2911 per share
Price / Cash96.20
Book Value$3.22 per share
Price / Book8.70

Profitability

EPS (Most Recent Fiscal Year)($0.22)
Net Income$-14,470,000.00
Net Margins-3.65%
Return on Equity-6.83%
Return on Assets-4.49%

Miscellaneous

Employees3,800
Outstanding Shares66,500,000
Market Cap$1,861.92

The Truth About Cryptocurrencies

NxStage Medical (NASDAQ:NXTM) Frequently Asked Questions

What is NxStage Medical's stock symbol?

NxStage Medical trades on the NASDAQ under the ticker symbol "NXTM."

How were NxStage Medical's earnings last quarter?

NxStage Medical, Inc. (NASDAQ:NXTM) issued its quarterly earnings results on Thursday, May, 10th. The medical device company reported ($0.02) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.02 by $0.04. The medical device company earned $107.30 million during the quarter, compared to analyst estimates of $106.95 million. NxStage Medical had a negative net margin of 3.65% and a negative return on equity of 6.83%. View NxStage Medical's Earnings History.

What price target have analysts set for NXTM?

8 analysts have issued 1-year price targets for NxStage Medical's stock. Their forecasts range from $30.00 to $30.00. On average, they anticipate NxStage Medical's stock price to reach $30.00 in the next year. This suggests a possible upside of 7.1% from the stock's current price. View Analyst Ratings for NxStage Medical.

What is the consensus analysts' recommendation for NxStage Medical?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NxStage Medical in the last year. There are currently 8 hold ratings for the stock, resulting in a consensus recommendation of "Hold."

Who are some of NxStage Medical's key competitors?

Who are NxStage Medical's key executives?

NxStage Medical's management team includes the folowing people:
  • Mr. Jeffrey H. Burbank, Founder, CEO & Director (Age 55)
  • Mr. Joseph E. Turk Jr., Pres (Age 50)
  • Mr. Matthew W. Towse, Sr. VP, CFO & Treasurer (Age 55)
  • Ms. Winifred L. Swan, Sr. VP, Gen. Counsel & Sec. (Age 54)
  • Dr. Allan J. Collins M.D., FACP, Head of Scientific Advisory Board and Chief Medical Officer

Has NxStage Medical been receiving favorable news coverage?

News coverage about NXTM stock has trended positive this week, according to Accern Sentiment Analysis. The research firm identifies positive and negative media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. NxStage Medical earned a coverage optimism score of 0.43 on Accern's scale. They also assigned news stories about the medical device company an impact score of 45.66 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

How do I buy shares of NxStage Medical?

Shares of NXTM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NxStage Medical's stock price today?

One share of NXTM stock can currently be purchased for approximately $28.00.

How big of a company is NxStage Medical?

NxStage Medical has a market capitalization of $1.86 billion and generates $393.94 million in revenue each year. The medical device company earns $-14,470,000.00 in net income (profit) each year or ($0.22) on an earnings per share basis. NxStage Medical employs 3,800 workers across the globe.

How can I contact NxStage Medical?

NxStage Medical's mailing address is 350 MERRIMACK STREET, LAWRENCE MA, 01843. The medical device company can be reached via phone at 978-687-4700 or via email at [email protected]


MarketBeat Community Rating for NxStage Medical (NASDAQ NXTM)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  267 (Vote Outperform)
Underperform Votes:  221 (Vote Underperform)
Total Votes:  488
MarketBeat's community ratings are surveys of what our community members think about NxStage Medical and other stocks. Vote "Outperform" if you believe NXTM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NXTM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.